Cerebyomysin

DESCRIPTION

Cerebrolysin (synonym FPE 1070) is a synthetic nootropic drug which consists of
low-molecular peptides and possesses neuroprotective and neurotrophic repair
properties. The active fragment of cerebrolysin is made of proteins with very low
molecular masses that do not exceed 10.000 daltons. This means they can penetrate
the blood-brain (or blood-SCF) barrier and reach neurons directly, making the drug
able to show organ-specific combined effects towards the brain.

Cerebrolysin has been proven to have neurotrophic action similar to nerve growth
factors, which cause peripheral and central neuronal stimulation. It improves
efficiency within the brain’s aerobic metabolic processes and improves intracellular
peptide synthesis. The neuroprotective properties of this nootropic agent help to
shield neurons from lactocidosis, to prevent formation of free radicals and to
decrease.

PROTOCOL

Content & Potency: 215.2mg/mL x 10mL x 4 vials : ready-to-inject subcutaneously
Suggested dosage: Inject 1ml daily for 5 days out of 7 (4 week course)
Oral option: 40 capsules at 215mcg – Take one capsule per day for 40 days (Ask for
availability)

CLINICAL RESEARCH

Cerebrolysin in Alzheimer’s disease: a randomized, double-blind,
placebo-controlled trial with a neurotrophic agent

M. Panisset, S. Gauthier, H. Moessler, M. Windisch
Summary: Cerebrolysin (Cere) is a compound with neurotrophic activity. It has
been shown to be effective in the treatment of Alzheimer’s disease (AD) in earlier
trials. In this multicenter, randomized, double-blind, placebo-controlled,
the parallel-group study, patients were injected intravenously with placebo or 30mL
Cere five days per week for four weeks. Effects on cognition and global function
were evaluated with the Alzheimer Disease Assessment Scale-Cognitive
Subscale (ADAS-Cog) and the Clinicians Interview-based Impression of Change
with Caregiver Input scale (CIBIC+) 4, 12, 24 weeks after the beginning of the
injections. 192 patients were enrolled, 95 were randomized to placebo, and 97 to
Cere. At baseline, there was a significant difference between groups for age, age of
the onset of dementia, and the number of patients with hallucinations. At week 12 there
was a significant difference on the CIBIC + (p=0.033) in favor of Cere. The number
of CIBIC+ responders (score < 4), was significantly higher (p=0.007), with 68 (76%)
in the Cere group and 51 (57%) in the placebo group. Trends were noted in the
Disability Assessment in Dementia scale and the Cornell Depression Scale.
Adverse events were recorded in 73% of placebo and 64% of Cere patients. Most
common adverse events were headaches, dizziness, weight loss and anxiety.
Conclusions: Cere treatment was well tolerated and resulted in significant
improvements in the global score two months after the end of active treatment.

Courtesy of: https://www.transformyouaz.com